SCHEMBL2749602

SCHEMBL2749602

Nc1ncc(-c2cnn(CC(=O)N3CCCCC3)c2)cc1-c1nc2ccccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 2/20 0.48
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
MET P08581 11/20 0.43
CCNC P24863 2/20 0.43
CDK8 P49336 2/20 0.43
FGFR1 P11362 1/20 0.43
FGFR2 P21802 1/20 0.43
FGFR3 P22607 1/20 0.43
MGLL Q99685 1/20 0.43
NPC1 O15118 2/20 0.43
HPGD P15428 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
JAK2 O60674 1/20 0.40
KDR P35968 1/20 0.40
JAK3 P52333 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748653 0.99 BTK (0.47) BTKALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL2748538 0.92 MET (0.45) BTKALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL2748024 0.92 MET (0.49) BTKALDH1A1METCCNCCDK8
SCHEMBL2749224 0.91 MET (0.47) BTKALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL2749147 0.91 MET (0.46) BTKALDH1A1SMN1; SMN2KMT2AMET
SCHEMBL2748875 0.88 MET (0.44) BTKMETFGFR1FGFR2FGFR3
SCHEMBL2749424 0.86 MET (0.49) ALDH1A1SMN1; SMN2KMT2AGAAMET
SCHEMBL2749951 0.86 MET (0.55) ALDH1A1SMN1; SMN2KMT2AGAAMET
SCHEMBL2749226 0.85 CCNC (0.47) METCCNCCDK8MGLLMAPK1
SCHEMBL2748451 0.85 MET (0.56) ALDH1A1SMN1; SMN2KMT2AGAAMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 BTK 316/4885ALDH1A1 945/4885SMN1; SMN2 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.